Results for tag: "Epidermal Growth Factor Receptor"

The Epidermal Growth Factor Receptor (EGFR) market is a subset of the Endocrine and Metabolic Disorders Drugs market. EGFR is a protein found on the surface of cells that helps regulate cell growth and division. It is involved in the development of many types of cancer, including non-small cell lung cancer, colorectal cancer, and head and neck cancer. EGFR inhibitors are drugs that block the activity of EGFR, preventing cancer cells from growing and dividing. These drugs are used to treat a variety of cancers, including those that are resistant to other treatments. EGFR inhibitors are a rapidly growing segment of the Endocrine and Metabolic Disorders Drugs market, with new drugs being developed to target specific types of cancer. These drugs are often used in combination with other treatments, such as chemotherapy and radiation therapy, to improve outcomes. Companies in the EGFR market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, and Pfizer. Show Less Read more